论文部分内容阅读
儿童急性淋巴细胞白血病(ALL)约70％可治愈,然而30％临床缓解后仍复发。影响预后的因素包括:临床(年龄<6个月或>15岁、男性、高瘤负荷),生物因素(WBC>100×10~9/l、Hb>10g/dl),免疫因素[CD10(+)、T免疫表型、髓系抗原表达],或遗传因素[(假二倍体、四倍体、t(9;22)、t(4;11)]。治疗的强度主要依据这些预后因素等进行低、中、高危险分类后进行。为了更有效的提高治疗效果及准确判断预后,作者应用分子生物学方法对51例儿童B-AIL诱导化疗后MRD进行了前瞻性研究,表明MRD水平高低为一个判断预后的重要指标。 病人与方法 1992年底至1996年11月收治的51例儿童B-ALL以据FRALLE92及FRALLE93方案进行治疗。在诊断时及诱导后(第35天),分别进行PCR检测。
About 70% of childhood acute lymphoblastic leukemia (ALL) is curable, yet 30% relapse after clinical remission. Factors affecting the prognosis include: clinical (age <6 months or> 15 years old, male, high tumor burden), biological factors (WBC> 100 × 10-9 / l, Hb> 10g / dl), immune factors T immunophenotype, myeloid antigen expression], or genetic factors [(diploid, tetraploid, t (9; 22), t (4; 11)]. The intensity of treatment is based primarily on these prognoses Factors such as low, medium and high risk classification carried out.In order to more effectively improve the treatment effect and accurately determine the prognosis, the authors applied molecular biology method of 51 children with B-AIL after induction chemotherapy MRD prospective study showed that MRD The level is an important indicator of prognosis.Patients and Methods 51 children with B-ALL treated from the end of 1992 to November 1996 were treated according to the FRALLE92 and FRALLE93 regimens.At the time of diagnosis and after induction (day 35), respectively, PCR test.